MEDIVATION INC (MDVN)
(Delayed Data from NSDQ)
$81.44 USD
+0.02 (0.03%)
Updated Sep 27, 2016 04:14 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[MDVN]
Reports for Purchase
Showing records 221 - 240 ( 252 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for MDVN
Provider: VALUENGINE, INC
Industry: Medical - Biomedical and Genetics
MONTHLY PORTFOLIO UPDATE
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Dimebon Failed, Prostate Cancer Drug may be Overvalued ? Lowering Rating
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Industry: Medical - Biomedical and Genetics
Dimebon Failed, Prostate Cancer Drug may be Overvalued ? Lowering Rating
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
An Exciting Time for Prostate Cancer - Initiating Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y